Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5197462
Max Phase: Preclinical
Molecular Formula: C77H97F3N10O10S4
Molecular Weight: 1507.94
Associated Items:
ID: ALA5197462
Max Phase: Preclinical
Molecular Formula: C77H97F3N10O10S4
Molecular Weight: 1507.94
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCC(=O)N2CCN(CC[C@H](CSc3ccccc3)Nc3ccc(S(=O)(=O)NC(=O)c4ccc(N5CCN(CC6=C(c7ccccc7)CCC(C)(C)C6)CC5)cc4)cc3S(=O)(=O)C(F)(F)F)CC2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C77H97F3N10O10S4/c1-52(54-23-25-56(26-24-54)70-53(2)81-51-102-70)82-73(95)66-45-61(91)49-90(66)74(96)71(75(3,4)5)84-68(92)21-15-10-16-22-69(93)89-43-37-86(38-44-89)36-34-59(50-101-62-19-13-9-14-20-62)83-65-32-31-63(46-67(65)103(97,98)77(78,79)80)104(99,100)85-72(94)57-27-29-60(30-28-57)88-41-39-87(40-42-88)48-58-47-76(6,7)35-33-64(58)55-17-11-8-12-18-55/h8-9,11-14,17-20,23-32,46,51-52,59,61,66,71,83,91H,10,15-16,21-22,33-45,47-50H2,1-7H3,(H,82,95)(H,84,92)(H,85,94)/t52-,59+,61+,66-,71+/m0/s1
Standard InChI Key: JUCOZKOKHJQKAI-RYWMMAFVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1507.94 | Molecular Weight (Monoisotopic): 1506.6224 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Zeng S, Huang W, Zheng X, Liyan Cheng, Zhang Z, Wang J, Shen Z.. (2021) Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges., 210 [PMID:33160761] [10.1016/j.ejmech.2020.112981] |
Source(1):